HyperCollar4D Radical Improvement of Cancer Treatment without Additional Negative Side Effects
- Coordinator
- Sensius BV, Netherlands
- Runs
- 1 January 2022 to 30 June 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €8.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190101940
What the project is doing
In the project's own words, from its summary on CORDIS.
We have developed a device called HyperCollar4D that significantly increases the effectiveness of radiotherapy for head and neck (H&N) cancer. The first results on 70 patients have proven that our technology yields +50% complete response with respect to radiotherapy alone. The HyperCollar4D is based on hyperthermia: warming up the tumor to 43 C improves its sensitivity to radiotherapy. Hyperthermia yields no lasting toxicity, unlike radiotherapy and chemotherapy.
The challenge with hyperthermia is delivering it effectively (i.e., heating only the tumor and not the nearby tissues) and cost-efficiently. The HyperCollar4D is the first device to achieve effective and cost-efficient hyperthermia treatments for H&N cancer. Our technology (called thermotherapy) is protected by two patents (one granted and one filed). The HyperCollar4D design is modular, so it can be extended to add modules to treat other kinds of cancers.
Sensius is a spin-off of the Erasmus Medical Center.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Sensius BV | Rotterdam | Netherlands | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI